<DOC>
	<DOCNO>NCT01605136</DOCNO>
	<brief_summary>This randomize placebo-controlled study conduct two parallel study arm six month period ( three dos ) . Between 75 100 eligible patient enrol . Patients receive afamelanotide ( 16 mg implant ) placebo accord follow dose regimen : - Group A administer afamelanotide implant Days 0 , 60 120 - Group B administer placebo implant Days 0 , 60 120 The number severity phototoxic reaction , type duration sun exposure , treatment-emergent adverse event use concomitant medication record patient study diary Days 0 180 . Quality life measure use DLQI EPP-QoL Days 0 , 60 , 120 180 . Participants visit clinic Days 60 , 120 180 assessment adverse event . A subset patient photoprovoked low back dorsal surface hand minimal symptom dose ( MSD ) determine Days 0 , 30 , 60 , 90 120 .</brief_summary>
	<brief_title>Phase III Confirmatory Study Erythropoietic Protoporphyria</brief_title>
	<detailed_description>Afamelanotide man-made drug study use preventative medication Erythropoietic Protoporphyria ( EPP ) sufferer . It synthetically produce analogue human alpha melanocyte stimulate hormone ( alpha-MSH ) yet available market . The purpose study look whether afamelanotide reduce number severity EPP symptoms patient exposed light . This study also look drug tolerate take people EPP . The study involve use implant , come form small rod administer skin . The implant may contain study drug afamelanotide placebo ( inactive medication ) . Over 620 subject treat afamelanotide date serious safety concern identify . For study , afamelanotide formulate controlled release depot injection ( implant ) . This mean afamelanotide release slowly body day . This study aim confirm photoprotective property afamelanotide demonstrate early Phase II phase III study .</detailed_description>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<mesh_term>alpha-MSH</mesh_term>
	<criteria>Male female subject characteristic symptom EPP phototoxicity biochemicallyconfirmed diagnosis EPP . Aged 18 year old ( inclusive ) . Able understand sign write Informed Consent Form . Willing take precaution prevent pregnancy completion study ( Day 180 ) . Any allergy afamelanotide polymer contain implant lidocaine local anesthetic use administration study medication EPP patient significant hepatic involvement Personal history melanoma dysplastic nevus syndrome . Current Bowen 's disease , basal cell carcinoma , squamous cell carcinoma , malignant premalignant skin lesion . Any photodermatosis polymorphic light eruption , actinic prurigo , discoid lupus erythematosus , chronic actinic dermatitis solar urticaria . Any evidence clinically significant organ dysfunction clinically significant deviation normal clinical laboratory determination . Acute history drug alcohol abuse ( last 6 month ) . Patient assess suitable study opinion Investigator ( e.g . noncompliance history , allergic local anesthetic , faint give injection give blood ) . Participation clinical trial investigational agent within 30 day prior screen visit . Prior concomitant therapy medication may interfere objective study , include drug cause photosensitivity skin pigmentation . Female pregnant ( confirm positive serum Î²HCG pregnancy test prior baseline ) lactating . Females childbearing potential ( premenopausal , surgically sterile ) use adequate contraceptive measure ( i.e . oral contraceptive , diaphragm plus spermicide , intrauterine device ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Erythropoietic Protoporphyria</keyword>
	<keyword>EPP</keyword>
	<keyword>Afamelanotide</keyword>
</DOC>